Drug Profile
BSL5 170327
Alternative Names: BSL5-170327C; BSL5-170327SLatest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator Kao Corporation
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for phase-I development in Skin-disorders(In volunteers) in Japan (Topical)
- 27 Oct 2017 Kao Corporation completes a phase I trial in Skin disorders (In volunteers) in Japan (Topical) (UMIN000027155)
- 19 May 2017 Phase-I clinical trials in Skin disorders (In volunteers) in Japan (Topical) (UMIN000027155)